home / stock / ions / ions news


IONS News and Press, Ionis Pharmaceuticals Inc. From 05/23/24

Stock Information

Company Name: Ionis Pharmaceuticals Inc.
Stock Symbol: IONS
Market: NASDAQ
Website: ionispharma.com

Menu

IONS IONS Quote IONS Short IONS News IONS Articles IONS Message Board
Get IONS Alerts

News, Short Squeeze, Breakout and More Instantly...

IONS - New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA(TM) (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)

New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) PR Newswire – Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and...

IONS - Biogen also drops collaboration with Ionis on Angelman syndrome candidate

2024-05-16 13:47:53 ET More on Biogen, Ionis Pharmaceuticals Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen and Ionis drop ALS candidate after trial setback Eisai projects major growth for Alzheimer's therapy L...

IONS - Biogen and Ionis drop ALS candidate after trial setback

2024-05-16 09:00:18 ET More on Biogen, Ionis, etc. Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Eisai projects major growth for Alzheimer's therapy...

IONS - Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impa...

IONS - Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome PR Newswire ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose leve...

IONS - Ionis to host 2024 virtual Annual Meeting of Stockholders

Ionis to host 2024 virtual Annual Meeting of Stockholders PR Newswire CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed ...

IONS - Tracking Tweedy Browne Portfolio - Q1 2024 Update

2024-05-15 06:47:21 ET Summary Tweedy Browne's 13F portfolio value increased to $2.13B, with 45 holdings. Berkshire Hathaway remains the largest position, followed by Alphabet, Johnson & Johnson, FMC Corporation, and Ionis Pharma. New stakes include Envista Holdings, while...

IONS - Trading (IONS) With Integrated Risk Controls

2024-05-12 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

IONS - Tweedy, Browne 2024 Client Letter

2024-05-11 06:50:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...

IONS - The 3 Most Undervalued Pharma Stocks to Buy in May 2024

2024-05-09 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here’s a question for you: What determines the value of a drug ? Is it the number of lives it saves or how much it costs to make? Is it the deadliness of the disease it prevents or t...

Previous 10 Next 10